In this video, Dr. Bardiès demonstrates the clinical application of nuclear medicine dosimetry using an anonymized patient dataset.

In this video, Dr. Bardiès explains the steps of a clinical dosimetry workflow in nuclear medicine.

In this video, Dr. Bardiès gives a short introduction about the concept of dosimetry for radiopharmaceuticals and explains the terminology routinely used for the procedure.

Advancements in gallium-based radiopharmaceuticals are transforming the landscape of oncologic diagnostics, with several agents already in routine clinical practice and more in development. Explore the techniques employed to produce the gallium-68 on both small and large scales to satisfy clinical and research needs.

Heloisa Soares examined the unmet need in managing neuroendocrine tumors (NETs), the impact of current phase 3 trials on the management of well-differentiated NETs, the role of molecular profiling in neuroendocrine neoplasm management, and how future guidelines for gastroenteropancreatic NETs may change with the recent theranostics developments.

Maribel del Olmo reviewed the advantages and disadvantages of somatostatin analogs for patients with somatostatin receptor-positive neuroendocrine tumors, the evolving treatment landscape for these patients, the necessary steps if a non-functional NET becomes functional during radiopharmaceutical therapy, and the promising advancements in innovative radiopharmaceuticals.

Watch Damian Wild discuss the role of nuclear medicine physicians in multidisciplinary oncology tumor boards, strategies for engaging oncologists in the theranostics-related management of their patients, and the future of dosimetry in clinical practice. He also shares valuable insights for young professionals exploring opportunities in theranostics.

In part two of this two-part video series, nuclear medicine physician Chiara Maria Grana and medical oncologist Jaume Capdevila share their key takeaways from ENETS 2025 directly from the ICE Kraków Congress Centre.

In part one of a two-part video series, nuclear medicine physician Chiara Maria Grana and medical oncologist Jaume Capdevila discussed the most exciting insights presented at the Annual Conference of the European Neuroendocrine Tumor Society e.V. (ENETS), which took place from March 5-7, 2025 at the ICE Kraków Congress Centre in Poland.

This webcast is from the satellite symposium titled “HOW TO SPEAK ‘THERANOSTICS’ IN NET: Translating Key Principles into Clinical Practice” that took place at the European Neuroendocrine Tumor Society (ENETS) Annual Congress on 6^th March 2025 in Krakow, Poland.

In this infographic, the focus is on circulating biomarkers for neuroendocrine neoplasms, which are highly clinically relevant. Learn all about them.

The following slide kit outlines the principles and steps for somatostatin receptor-based imaging, specifically in managing neuroendocrine tumors.

Current functional imaging techniques in nuclear medicine, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), play an essential role in clinical oncology by aiding early diagnosis, predicting treatment responses, and monitoring the disease. Do you know the key differences between these two techniques?

Learn about the concept of theranostics in oncology and how radiopharmaceuticals, diagnostic and therapeutic compounds labeled with radionuclides, play a central role in this approach.​

Find out the difference between the production of carrier-added versus non-carrier-added lutetium-177, a radioisotope of choice for targeted radiopharmaceutical therapy.

Most medical-grade radionuclides used in synthesizing diagnostic and therapeutic radiopharmaceuticals are produced through one of the four methods of nuclear activation: fission, neutron activation, cyclotron and generator systems. Find out more in the infographic.​

Discover the steps involved in a typical dosimetry workflow and compare the benefits and challenges of the dosimetry-based approach to targeted radiopharmaceutical therapy with a one-size-fits-all approach.​

Learn more about targeted radiopharmaceutical therapy and the mechanism of action of radiotherapeutic agents used for the treatment of tumors expressing specific receptors on their surface.

Somatostatin signaling is an important pathway involved in the pathophysiology of neuroendocrine tumors (NETs) that allows a personalized theranostic approach to their management.

Explore this interactive patient case to learn more about the diagnosis and management of pancreatic neuroendocrine tumors. This case study, which covers several lines of treatment, was kindly provided by Dr. Jaume Capdevila.

This e-book chapter presents the diagnosis and management of patients with pheochromocytomas, paragangliomas, neuroblastomas and medullary thyroid carcinomas.  It also features a clinical case in which radiopharmaceutical therapy was recommended. Additionally, it also presents the potential of radiopharmaceutical therapy in meningiomas.

This e-book chapter provides an overview of the current knowledge on diagnosing and treating gastroenteropancreatic and pulmonary neuroendocrine tumors, focusing on the indications of radiopharmaceutical therapy. Two clinical cases are also included.

Watch experts discussing the topic of 'Navigating the winding road of NET patient treatment - A multidisciplinary expert opinion.' The event took place during the ENETS 2024 in Vienna.

Andrea Frilling discusses the reasons why some patients with neuroendocrine tumors (NETs) are not eligible for curative surgical treatment, the current state of neoadjuvant and adjuvant therapies for NET patients, the available treatment options for NET patients who have liver metastasis, and the main highlight from ENETS 2024. 

Wouter de Herder explains the critical role of endocrinology in managing patients with neuroendocrine neoplasms, the principles of somatostatin analog therapy and identifies the groups of neuroendocrine tumor (NET) patients who benefit most from it, the recommended second-line treatment for patients with advanced, unresectable, or metastasized gastroentero-pancreatic NET after recurrence with somatostatin analogs, and the main highlights from ENETS 2024.

Julien Hadoux describes various ways to improve the early and accurate diagnosis and treatment of patients with neuroendocrine tumors (NETs), the present and future aspects of molecular profiling in the management of NETs, the use of radiopharmaceutical therapy (RPT) compared to other systemic targeted therapies in the treatment sequence of patients with NETs, and the main highlights from ENETS 2024. 

Paola Erba discusses the use of FDG PET/CT in conjunction with somatostatin receptor imaging for the initial staging of patients with neuroendocrine tumors, how the recent developments in theranostics have influenced guidelines and recommendations for treating neuroendocrine tumors (NETs), the challenges and needs for expanding access to radiopharmaceutical treatment (RPT), and the main highlights from the ENETS 2024.

Thor Halfdanarson talks about the multidisciplinary care approach to treating patients with neuroendocrine tumors (NETs), imaging techniques for initial staging, restaging and monitoring the effectiveness of treatment in NET patients, the variations in the treatment guidelines for NETs between Europe and the USA and the main takeaways from ENETS 2024. 

This virtual webinar was conducted by the European Society of Surgical Oncology (ESSO) on 22^nd November 2023.

Prof. Grana provides an overview of the main issues and challenges currently facing PRRT and its role in managing NETs.

Prof. Capdevila shares his views on the potential impact of ongoing phase III studies on the guidelines for managing well-differentiated neuroendocrine tumors.

Professor Nagarajah guides us through the latest developments in PSMA-targeting radiopharmaceuticals and shares his views on the role of dosimetry in radionuclide therapy.

Discover how the recent advancements in theranostics have revolutionized nuclear medicine through Prof. Pubul Núñez's insightful explanation.

Highly precise radiopharmaceuticals can be used to effectively diagnose or treat tumors expressing specific receptors on their surface. Watch the video to learn more about their mode of action (MoA).

This virtual webinar was conducted by the European Society of Surgical Oncology (ESSO) on 17^th May 2023.

Watch experts discussing the topic of 'Developments in Theranostics and Neuroendocrine Tumors.' The event took place during the ENETS 2023 in Vienna.